Rani Therapeutics (RANI) News Today → Bill Clinton Backing Biden Replacement??? (From The Freeport Society) (Ad) Free RANI Stock Alerts $4.15 -0.24 (-5.47%) (As of 06/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 3, 2024 | americanbankingnews.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Rating of "Buy" from AnalystsJune 3, 2024 | marketbeat.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Recommendation of "Buy" from AnalystsRani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) has earned a consensus rating of "Buy" from the six ratings firms that are presently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average 1-year price target among brokers thatMay 31, 2024 | marketbeat.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Short Interest Down 29.7% in MayRani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) was the recipient of a significant drop in short interest in the month of May. As of May 15th, there was short interest totalling 871,200 shares, a drop of 29.7% from the April 30th total of 1,240,000 shares. Based on an average daily volume of 148,400 shares, the short-interest ratio is presently 5.9 days. Currently, 7.5% of the shares of the company are sold short.May 14, 2024 | globenewswire.comRani Therapeutics to Participate in May Investor ConferencesMay 12, 2024 | marketbeat.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Short Interest Down 27.9% in AprilRani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) was the recipient of a significant drop in short interest during the month of April. As of April 30th, there was short interest totalling 1,240,000 shares, a drop of 27.9% from the April 15th total of 1,720,000 shares. Currently, 10.9% of the shares of the company are short sold. Based on an average daily trading volume, of 144,600 shares, the days-to-cover ratio is currently 8.6 days.May 12, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Warby Parker (WRBY) and Adaptive Biotechnologies (ADPT)May 9, 2024 | marketbeat.comRani Therapeutics (NASDAQ:RANI) PT Raised to $14.00BTIG Research boosted their target price on shares of Rani Therapeutics from $7.00 to $14.00 and gave the stock a "buy" rating in a report on Thursday.May 9, 2024 | marketbeat.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Buy" from AnalystsShares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have been assigned an average rating of "Buy" from the six brokerages that are covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12-month price target among aMay 9, 2024 | msn.comRANI: 1Q:24 ResultsMay 9, 2024 | globenewswire.comRani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024May 8, 2024 | markets.businessinsider.comEdward Nash Maintains Buy Rating on Rani Therapeutics Amid Strong Financials and Promising Clinical TrialsMay 7, 2024 | finance.yahoo.comRani Therapeutics Q1 2024 Earnings: Financial Performance and Strategic UpdatesMay 7, 2024 | marketbeat.comHC Wainwright Raises Rani Therapeutics (NASDAQ:RANI) Price Target to $13.00HC Wainwright boosted their target price on shares of Rani Therapeutics from $12.00 to $13.00 and gave the company a "buy" rating in a research note on Tuesday.May 6, 2024 | investorplace.comRANI Stock Earnings: Rani Therapeutics Hldgs Beats EPS for Q1 2024May 6, 2024 | globenewswire.comRani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate UpdateMay 2, 2024 | finance.yahoo.comFavourable Signals For Rani Therapeutics Holdings: Numerous Insiders Acquired StockApril 23, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Corcept Therapeutics (CORT), Structure Therapeutics, Inc. Sponsored ADR (GPCR)April 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Astria Therapeutics (ATXS) and Aslan Pharmaceuticals (ASLN)April 14, 2024 | seekingalpha.comRANI Rani Therapeutics Holdings, Inc.April 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT), Liquidia Technologies (LQDA) and Xtant Medical Holdings (XTNT)March 27, 2024 | marketbeat.comCanaccord Genuity Group Trims Rani Therapeutics (NASDAQ:RANI) Target Price to $9.00Canaccord Genuity Group dropped their price target on Rani Therapeutics from $21.00 to $9.00 and set a "buy" rating for the company in a research note on Wednesday.March 27, 2024 | marketbeat.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Consensus Recommendation of "Buy" by AnalystsShares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have received a consensus rating of "Buy" from the five ratings firms that are currently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a buy recommendation. The average 12 moMarch 25, 2024 | markets.businessinsider.comBuy Rating for Rani Therapeutics: Promising Clinical Data and Significant Market PotentialMarch 25, 2024 | marketbeat.comRani Therapeutics (NASDAQ:RANI) PT Lowered to $12.00 at HC WainwrightHC Wainwright reduced their price target on shares of Rani Therapeutics from $16.00 to $12.00 and set a "buy" rating for the company in a research note on Monday.March 22, 2024 | seekingalpha.comRani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | msn.comRANI: 2023 ResultsMarch 21, 2024 | finance.yahoo.comQ4 2023 Rani Therapeutics Holdings Inc Earnings CallMarch 21, 2024 | finance.yahoo.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | investorplace.comRANI Stock Earnings: Rani Therapeutics Hldgs Beats EPS for Q4 2023March 20, 2024 | benzinga.comRecap: Rani Therapeutics Hldgs Q4 EarningsMarch 20, 2024 | globenewswire.comRani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate UpdateMarch 19, 2024 | benzinga.comEarnings Outlook For Rani Therapeutics HldgsMarch 16, 2024 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Verastem (VSTM), Akebia Therapeutics (AKBA)March 16, 2024 | finance.yahoo.comRANI Apr 2024 2.500 putMarch 15, 2024 | finance.yahoo.comRANI Apr 2024 5.000 putMarch 15, 2024 | globenewswire.comRani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial ResultsMarch 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Incyte (INCY)March 12, 2024 | finance.yahoo.comIndividual investors own 40% of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shares but private companies control 47% of the companyMarch 2, 2024 | marketbeat.comRani Therapeutics (NASDAQ:RANI) Stock Price Down 1.3%Rani Therapeutics (NASDAQ:RANI) Shares Down 1.3%February 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Arcus Biosciences (RCUS) and United Therapeutics (UTHR)February 20, 2024 | finance.yahoo.comRANI: INITIATION – Realizing Oral Administration of BiologicsFebruary 19, 2024 | bizjournals.comSilicon Valley businesswomen share thoughts on mentoringFebruary 9, 2024 | marketbeat.comWedbush Analysts Lower Earnings Estimates for Rani Therapeutics Holdings, Inc. (NASDAQ:RANI)Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Free Report) - Analysts at Wedbush decreased their FY2027 earnings per share (EPS) estimates for shares of Rani Therapeutics in a report issued on Tuesday, February 6th. Wedbush analyst A. Argyrides now anticipates that the company will earn ($1.78)February 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rani Therapeutics Holdings on Strong Clinical and Strategic ProspectsFebruary 6, 2024 | msn.comRani Therapeutics Reports Positive Phase 1 Trial OutcomesFebruary 6, 2024 | msn.comRani Therapeutics Shares Exciting Clinical Trial ResultsFebruary 6, 2024 | marketbeat.comWedbush Reaffirms Outperform Rating for Rani Therapeutics (NASDAQ:RANI)Wedbush restated an "outperform" rating and issued a $8.00 price objective on shares of Rani Therapeutics in a research report on Tuesday.February 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rani Therapeutics on Strong Clinical and Strategic MilestonesFebruary 5, 2024 | marketwatch.comRani Therapeutics Sees Positive Results From Trial for CT-P43February 5, 2024 | markets.businessinsider.comRani Reports Positive Topline Results From Phase 1 Clinical Study Of RT-111 Get Rani Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter. Email Address Bill Clinton Backing Biden Replacement??? (Ad)Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be Trump. Click here to see why it will be ______ _________. RANI Media Mentions By Week RANI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RANI News Sentiment▼0.000.74▲Average Medical News Sentiment RANI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RANI Articles This Week▼02▲RANI Articles Average Week Get Rani Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PASG News GRCL News TYRA News GYRE News ARQT News IRON News SPRY News IMNM News ABVX News CNTA News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RANI) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredDON’T buy gold until you read thisIf you're an American who understands that your money is rotting away as you read this email… Then this is ...Sasco Gold LLC | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredNvidia needs this one obscure firm In my new investigation, I detail why this is the single most important factor in the future of AI. I expla...Porter & Company | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored